A world-first trial lead by the National Drug Research Institute (NDRI) will establish if N-Acetyl Cysteine (NAC) can reduce cravings and addiction to meth.

Lead researcher and NDRI Associate Professor Rebecca McKetin said NAC helped to reduce cravings by restoring the balance of chemicals in the brain that are involved in craving and drug seeking, making it easier for people to manage their desire for the drug.

The free trial is being conducted at several universities including Monash University and Deakin University in Geelong.

Western Region Drug and Alcohol (WRAD) centre director Geoff Soma said the trial was a positive step towards treating people with addiction.  

He said a suitable trial and proper evaluation period was required to establish whether the medication would make a positive contribution to treatment.

"There are a lot of people that are investing in trying to address the serious issues around psychological and physical addiction to ice,” he said. "Any progress made in treating an ice addiction is beneficial to the community.  It will be good to see how much (NAC) can add to the good work that is already being done in our region." 

During the trial participants will take two capsules of NAC morning and night for 12 weeks, with weekly assessments to monitor drug use and mood. Following a final medical assessment, the supply of NAC will conclude and a referral to other services will be made available. Mr Soma said like with any withdrawal program, it was important to ensure proper medical intervention and open discussions were available.